ZHONGHUA YANGSHENG BAOJIAN ›› 2023, Vol. 41 ›› Issue (3): 45-48.

Previous Articles     Next Articles

Adverse Reaction Analysis and Clinical Evaluation of Docetaxel Combined with Different Antineoplastic Drugs in Breast Cancer

HUANG Xiao-ting1, GUO Dai-nian2, FANG Ling1, ZHANG Han-zeng3,*   

  1. 1. Department of Pharmacy, Affiliated Cancer Hospital of Shantou University School of Medicine, Shantou Guangdong 515000, China;
    2. Clinical Drug Trials, Affiliated Cancer Hospital of Shantou University School of Medicine, Shantou Guangdong, 515000, China;
    3. Intravenous Center, Affiliated Cancer Hospital of Shantou University School of Medicine, Shantou Guangdong, 515000, China
  • Online:2023-02-01 Published:2023-02-06

PDF (PC)

29

Abstract: Objective To investigate the adverse reaction analysis and clinical evaluation of docetaxel combined with different antineoplastic drugs in breast cancer. Methods A retrospective study was conducted to select 78 breast cancer patients from March 2020 to March 2021 in the Affiliated Cancer Hospital of Shantou University Medical College. According to different treatment schemes, they were divided into three groups: TH (Docetaxel+Trastuzumab) group with 24 cases, TE (Docetaxel+Epirubicin) group with 25 cases, and TEC (Docetaxel+Epirubicin+Cyclophosphamide) group with 29 cases. The clinical efficacy, adverse reactions, serum biochemical index and 1-year survival rate of the three groups were compared. Results The therapeutic of TH group was significantly higher than that of TE group (P<0.05); the therapeutic of TEC group was significantly higher than that of TE group (P<0.05); the difference of curative effect between TH group and TEC group was not statistically significant (P>0.05). The adverse reactions of the three groups were mild, and there was no significant difference among the three groups (P>0.05). Compared with the 1-year survival rate of the three groups, the differences were statistically significant (P<0.05), among which the differences were statistically significant (P<0.05). The 1-year survival rate of TEC group was significantly higher than that of TE group (P<0.05), but there was no statistical difference between the other two groups (P>0.05). There was no significant difference in FSH and E2 between the three groups (P>0.05). Conclusion The efficacy and safety of Docetaxel combined with Trastuzumab is similar to that of Docetaxel combined with Epirubicin and Cyclophosphamide in the treatment of breast cancer, both of which are superior to those of Docetaxel and Epirubicin. Moreover, Docetaxel combined with Epirubicin and Cyclophosphamide has the best effect in inhibiting tumor cell proliferation, and the survival rate is higher than that of Docetaxel and Epirubicin, which can be selected according to the patient's condition.

Key words: breast cancer, docetaxel, trastuzumab, epirubicin, cyclophosphamide

CLC Number: